Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25306337 | 0.82 | KMT2A (0.49) | KMT2AATMALDH1A1RAB9AAGTR1 | |
| SCHEMBL25306705 | 0.79 | ALDH1A1 (0.49) | KMT2AALDH1A1RAB9AGAAAPP | |
| SCHEMBL13347759 | 0.71 | KMT2A (0.50) | KMT2AATMALDH1A1CYP11B1RAB9A | |
| SCHEMBL18086519 | 0.70 | GAA (0.62) | ALDH1A1CYP11B1GAAHDAC1 | |
| SCHEMBL5746471 | 0.69 | CA3 (0.48) | ALDH1A1 | |
| SCHEMBL10556740 | 0.68 | ESR1 (0.59) | KMT2AALDH1A1RAB9AGAAAPP | |
| SCHEMBL3596019 | 0.68 | ALDH1A1 (0.60) | KMT2AALDH1A1APP | |
| SCHEMBL3596015 | 0.68 | ALDH1A1 (0.60) | KMT2AALDH1A1APP | |
| SCHEMBL11635769 | 0.67 | MAOB (0.47) | KMT2AALDH1A1RAB9AMEN1 | |
| SCHEMBL29088689 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. | 2024-12-26 | — | — | US | disclosed |
| EP-4466266-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | KMT2A 1097/4885ATM 3469/4885ALDH1A1 760/4885 |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | KMT2A 1097/4885ATM 3469/4885ALDH1A1 760/4885 |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR1A | KMT2A 225/4885ATM 3916/4885ALDH1A1 659/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | KMT2A 1097/4885ATM 3469/4885ALDH1A1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.